Freenome, Inc. (FRNM)
| Market Cap | 1.31B +1,291.1% |
| Revenue (ttm) | 34.24M +1,528.8% |
| Net Income | -225.03M |
| EPS | -8.47 |
| Shares Out | 112.86M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 611,453 |
| Open | 11.73 |
| Previous Close | 11.55 |
| Day's Range | 11.40 - 11.89 |
| 52-Week Range | 9.95 - 14.47 |
| Beta | 0.35 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 1, 2026 |
About FRNM
Freenome, Inc. operates as a biotechnology company focused on developing blood-based tests for early cancer detection using artificial intelligence and multiomics technology. The company develops and provides blood-based tests for early cancer detection, including a test for colorectal cancer screening. It offers a multiomics platform that combines computational biology, machine learning, and multiple data types to identify biomarkers and detect various cancers. The company conducts clinical research programs, such as the PREEMPT CRC, Sanderson... [Read more]
Financial Performance
In 2025, Freenome's revenue was $30.41 million, an increase of 955.14% compared to the previous year's $2.88 million. Losses were -$219.34 million, -22.02% less than in 2024.
Financial StatementsNews
FDA Grants Breakthrough Device Designation to Freenome's Blood-Based SimpleScreen™ Lung Cancer Screening Test
BRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (Nasdaq: FRNM), an early cancer detection company developing blood-based screening tests, today announced that the U.S. Food and Drug...
FDA approves Freenome's blood test for colorectal cancer screening
The U.S. FDA has approved Freenome's blood-based colorectal cancer screening test for older adults, paving the way for partner Abbott to launch it in the U.S. this fall, the companies said on Monday...
FDA Approves Freenome's SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
– Approval expands colorectal cancer screening options for the up to 60 million Americans who are overdue for screening – – Medicare coverage and American Cancer Society guidance support broader acces...
Freenome Debuts as a Publicly Traded Company Focused on Blood-Based Early Cancer Detection
– Freenome common stock expected to begin trading on the Nasdaq Capital Market under the ticker symbol "FRNM" on July 21, 2026 – – Gross proceeds to Freenome totaled more than $300 million through a P...